such as "Introduction", "Conclusion"..etc
in the United Kingdom and Russia are reporting identification of a
long-sought chink in the armor of the parasite that causes African
sleeping sickness, a parasitic disease that kills at least 50,000
people each year. Their study appears in the current edition of ACS Chemical Biology, a monthly journal.
In the study, Michael Ferguson and colleagues cite an “urgent” need
for new treatments for the disease, which is spread by the tsetse fly
and also affects cattle — a precious possession that represents a bank
account on four feet to impoverished people in sub-Sahara Africa.
Current treatments for African sleeping sickness, Ferguson says, are
not only difficult to administer, but also expensive and toxic.
Their research identified the first compound to impede a key step in
an essential biochemical pathway in the sleeping sickness parasite.
Blocking this pathway disrupts the production of a key glycolipid that
anchors protective proteins to the surface of the parasite. The
analysis also revealed notable differences between pathways of
parasitic and human cells, which could reveal insight into possible
News release courtesy of American Chemical Society on October 22, 2008.
Enter the code exactly as it appears. All letters are case insensitive.